Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 1, 2013, Pages 300-305

  Chen, Xiqun ^a   Burdett, Thomas C ^a   Desjardins, Cody A ^a   Logan, Robert ^a   Cipriani, Sara ^a   Xu, Yuehang ^a   Schwarzschild, Michael A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLANTOIN; OXIDOPAMINE; URATE; URATE OXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL STRUCTURE; CIRCLING BEHAVIOR; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; GENE MUTATION; GENE OVEREXPRESSION; MOUSE; NERVE DEGENERATION; NEUROCHEMISTRY; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRIATE CORTEX;

ALLANTOIN; ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; BRAIN; DOPAMINE; DOPAMINERGIC NEURONS; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MOVEMENT; OXIDOPAMINE; PARKINSONIAN DISORDERS; URATE OXIDASE; URIC ACID;

MUS; MUS MUSCULUS; RODENTIA;

EID: 84871954612     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1217296110     Document Type: Article

References (43)

1. Wu XW, Lee CC, Muzny DM, Caskey CT (1989) Urate oxidase: primary structure and evolutionary implications. Proc Natl Acad Sci USA 86(23):9412-9416. (Pubitemid 20010436)
2. Johnson RJ, Lanaspa MA, Gaucher EA (2011) Uric acid: A danger signal from the RNA world that may have a role in the epidemic of obesity, metabolic syndrome, and cardiorenal disease: Evolutionary considerations. Semin Nephrol 31(5):394-399.
3. Ames BN, Cathcart R, Schwiers E, Hochstein P (1981) Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis. Proc Natl Acad Sci USA 78(11):6858-6862. (Pubitemid 12216861)
4. Álvarez-Lario B, Macarrón-Vicente J (2010) Uric acid and evolution. Rheumatology (Oxford) 49(11):2010-2015.
5. Constantinescu R, Zetterberg H (2011) Urate as a marker of development and progression in Parkinson's disease. Drugs Today (Barc) 47(5):369-380.
6. Chen X, Wu G, Schwarzschild MA (2012) Urate in Parkinson' s disease: More than a biomarker? Curr Neurol Neurosci Rep 12(4):367-375.
7. Schapira AH, Tolosa E (2010) Molecular and clinical prodrome of Parkinson disease: Implications for treatment. Nat Rev Neurol 6(6):309-317.
8. ClinicalTrials.gov. Safety of Urate Elevation in Parkinson's Disease (SURE-PD). Available at http://clinicaltrials.gov/ct2/show/NCT00833690. Accessed December 2, 2012.
9. Usuda N, Reddy MK, Hashimoto T, Rao MS, Reddy JK (1988) Tissue specificity and species differences in the distribution of urate oxidase in peroxisomes. Lab Invest 58(1):100-111. (Pubitemid 18042446)
10. Kono H, Chen CJ, Ontiveros F, Rock KL (2010) Uric acid promotes an acute inflammatory response to sterile cell death in mice. J Clin Invest 120(6):1939-1949.
11. Wu X, et al. (1994) Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc Natl Acad Sci USA 91(2):742-746. (Pubitemid 24041478)
12. Serra PA, et al. (2002) The neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine induces apoptosis in mouse nigrostriatal glia. Relevance to nigral neuronal death and striatal neurochemical changes. J Biol Chem 277(37):34451-34461.
13. Yu ZF, Bruce-Keller AJ, Goodman Y, Mattson MP (1998) Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res 53(5):613-625. (Pubitemid 28380802)
14. Romanos E, Planas AM, Amaro S, Chamorro A (2007) Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab 27(1):14-20. (Pubitemid 46006580)
15. Koprowski H, Spitsin SV, Hooper DC (2001) Prospects for the treatment of multiple sclerosis by raising serum levels of uric acid, a scavenger of peroxynitrite. Ann Neurol 49(1):139. (Pubitemid 32163024)
16. Du Y, Chen CP, Tseng CY, Eisenberg Y, Firestein BL (2007) Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. Glia 55(5):463-472. (Pubitemid 46383176)
17. Scott GS, Cuzzocrea S, Genovese T, Koprowski H, Hooper DC (2005) Uric acid protects against secondary damage after spinal cord injury. Proc Natl Acad Sci USA 102(9):3483-3488. (Pubitemid 40328071)
18. Zhu TG, et al. (2012) Protective effects of urate against 6-OHDA-induced cell injury in PC12 cells through antioxidant action. Neurosci Lett 506(2):175-179.
19. Jones DC, Gunasekar PG, Borowitz JL, Isom GE (2009) Dopamine induced apoptosis is mediated by oxidative stess and is enhanced by cyanide in differentiated PC12 cells. J Neurochem 74:2296-2304.
20. Guerreiro S, et al. (2009) Protection of midbrain dopaminergic neurons by the endproduct of purine metabolism uric acid: Potentiation by low-level depolarization. J Neurochem 109(4):1118-1128.
21. Duan W, et al. (2002) Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 80(1):101-110. (Pubitemid 34614582)
22. Irizarry MC, et al. (2009) Plasma urate and progression of mild cognitive impairment. Neurodegener Dis 6(1-2):23-28.
23. Auinger P, Kieburtz K, McDermott MP (2010) The relationship between uric acid levels and Huntington' s disease progression. Mov Disord 25(2):224-228.
24. Church WH, Ward VL (1994) Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. Brain Res Bull 33(4):419-425.
25. Bogdanov M, et al. (2008) Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 131(Pt 2):389-396. (Pubitemid 351197614)
26. Cipriani S, et al. (2012) Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease. PLoS ONE 7(5):e37331.
27. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M (2006) Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci 29(11):647-654. (Pubitemid 44602262)
28. Burnstock G (2008) Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov 7(7):575-590.
29. Terpstra B. Purine nucleoside mediated neuroprotection in the 6-hydroxydopamine rodent model of Parkinson's disease. Available at http://etd.ohiolink.edu/view.cgi?acc-num=ucin1298395215. Accessed December 2, 2012.
30. Hersh field MS, et al. (2010) Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. Proc Natl Acad Sci USA 107(32):14351-14356.
31. Sinha S, Singh SN, Ray US (2009) Total antioxidant status at high altitude in low-landers and native highlanders: Role of uric acid. High Alt Med Biol 10(3):269-274.
32. Tsukimori K, Yoshitomi T, Morokuma S, Fukushima K, Wake N (2008) Serum uric acid levels correlate with plasma hydrogen peroxide and protein carbonyl levels in preeclampsia. Am J Hypertens 21(12):1343-1346.
33. Bagnati M, et al. (1999) When and why a water-soluble antioxidant becomes prooxidant during copper-induced low-density lipoprotein oxidation: A study using uric acid. Biochem J 340(Pt 1):143-152. (Pubitemid 29251101)
34. Patterson RA, Horsley ET, Leake DS (2003) Prooxidant and antioxidant properties of human serum ultrafiltrates toward LDL: Important role of uric acid. J Lipid Res 44(3):512-521. (Pubitemid 37279698)
35. Santos CX, Anjos EI, Augusto O (1999) Uric acid oxidation by peroxynitrite: Multiple reactions, free radical formation, and amplification of lipid oxidation. Arch Biochem Biophys 372(2):285-294. (Pubitemid 30026778)
36. Kelly SJ, et al. (2001) Diabetes insipidus in uricase-deficient mice: A model for evaluating therapy with poly(ethylene glycol)-modified uricase. J Am Soc Nephrol 12(5):1001-1009. (Pubitemid 32378341)
37. Kao MP, Ang DS, Pall A, Struthers AD (2010) Oxidative stress in renal dysfunction: Mechanisms, clinical sequelae and therapeutic options. J Hum Hypertens 24(1):1-8.
38. D'Apolito M, et al. (2010) Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure. J Clin Invest 120(1):203-213.
39. Jackson-Lewis V, Blesa J, Przedborski S (2012) Animal models of Parkinson's disease. Parkinsonism Relat Disord 18(Suppl 1):S183-S185.
40. Gong L, et al. (2012) Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: Linking to Akt/GSK3β signaling pathway. J Neurochem 123(5):876-885.
41. Burdett TC, et al. (2012) Efficient determination of purine metabolites in brain tissue and serum by high-performance liquid chromatography with electrochemical and UV detection. Biomed Chromatogr, 10.1002/bmc.2760.
42. Xiao D, et al. (2006) Forebrain adenosine A2A receptors contribute to L-3,4-dihy-droxyphenylalanine- induced dyskinesia in hemiparkinsonian mice. J Neurosci 26(52):13548-13555. (Pubitemid 46026487)
43. Kachroo A, et al. (2005) Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J Neurosci 25(45):10414-10419. (Pubitemid 41628445)